Heart Disease Risk Factors in Major Depression
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
About this trial
This is an observational trial for Adrenal Gland Hyperfunction focused on measuring Cardiovascular Disease, Glucose Clamp, Hypercortisolism, Insulin Sensitivity, Major Depression Disorder, Inflammation, Coagulation, Metabolic, Insulin, Cytokine, Depression, Volunteer, Healthy Volunteer
Eligibility Criteria
INCLUSION CRITERIA Adults between the ages of 21 and 55, with or without major depression as diagnosed with The Structured Clinical Interview of Diagnosis (SCID) of the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV), will be recruited. All depressed patients will be included, although we will characterize patients a priori as having a predominantly melancholic, atypical, or mixed symptom pattern. We plan to recruit at least 20 patients in each group. Both currently depressed patients (greater than 14 on the Hamilton Depression Rating Scale) and those with a history of major depression who are clinically recovered will be included. Patients may be taking psychotropic medications for depression at the time of study. Sub-analyses will be done comparing steady-state glucose utilization rates as a function of mood state and medication status. Subjects should not have significant underlying illnesses known to affect insulin sensitivity, and should have a body mass index between 20 and 30 kg/m2. EXCLUSION CRITERIA Pregnancy Existing diabetes mellitus Body mass index less than 20 or greater than 30 kg/ m2 Existing cardiovascular diseases and other end organ diseases Existing peripheral vascular disease HIV infection Patients who are on B-blockers, thiazides, and/or glucocorticoids and cannot discontinue these medications. Subjects who are on oral contraceptives need to discontinue the medication for 1-2 days before the clamp study.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike